Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience

Table 1 Baseline characteristics and demographics of 44 patients with acute severe ulcerative colitis receiving infliximab n (%)

Characteristic	All patients (n = 44)
Age at index admission1	35.7 ± 15.9
Female	16 (36.4)
Extent of disease (Montreal classification)
E1 (limited to rectum)	2 (4.5)
E2 (distal to splenic flexure)	13 (29.5)
E3 (proximal to splenic flexure)	29 (65.9)
Current or previous smoker	18 (40.9)
Prescribed oral 5-ASA on admission	24 (54.5)
Prescribed thiopurine on admission	14 (31.8)
Median disease duration, in days, prior to first IFX infusion (IQR)	409 (16.25 to 1896.5)
First presentation of UC	12 (27.3)
Mean CRP (mg/L) on day of admission1	90.1 ± 81.9
CRP ≤ 5 on day of admission	6 (13.6)
Mean number of stools per day on admission1	12.1 ± 5.8

¹Data are presented as mean ± SD. UC: Ulcerative colitis; IQR: Interquartile range; 5-ASA: 5-aminosalicylate; CRP: C-reactive protein; IFX: Infliximab.